Cyplasin Biomedical Ltd Announces Second U.S. Patent for Cyplasin


    EDMONTON, Nov. 2 /CNW/ - Cyplasin Biomedical Ltd today announced that its
U.S. Patent application Nr 10/501,098 entitled "Cytotoxic Cyplasin of the Sea
Hare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive
Recombinants" has been granted as US patent Number US 7,271,242 B2. The patent
claims cover the production of a cytotoxic protein by mammalian cells and its
use to treat cancer.
    "This patent is an important milestone to define our intellectual
property for the production method of the cytotoxic cyplasin and related
proteins and its application as a substance to treat cancer. With the two US
patents now in our possession, the Company will concentrate all its efforts to
achieve a fast and successful development of cyplasin", said Professor
Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.

    About Cyplasin-SC(TM)

    Cyplasin-SC(TM) has demonstrated a selective ability to rapidly kill
certain types of cancer cells while leaving normal non-cancerous cells
untouched. Cyplasin-SC is a protein originally discovered and isolated by
Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The
protein can now be manufactured as a recombinant protein which allows the
company to develop the protein as an anti-cancer therapeutic product. Patents
have been issued to the Company covering the Cyplasin-SC protein.

    About Cyplasin Biomedical Ltd. (CBL)

    Founded in 2007 and headquartered in Edmonton, Canada with a research
laboratory close to Berlin, Germany, CBL is dedicated to bringing new
anticancer therapeutics to the marketplace. The Company's current goal is to
develop and commercialize the anticancer properties of Cyplasin-SC(TM) against
skin cancer and melanoma. CBL is publicly traded (CYPL: OTCBB)

    Forward-Looking Statements

    This press release includes and is based, inter alia, on forward-looking
information and statements that are subject to risks and uncertainties that
could cause actual results to differ. Such forward-looking information and
statements are based without limitation, as statements regarding future drug
development activities, anticipated products, or anticipated future revenues,
benefits or advantages, and the future plans and objectives of the Company,
that involve inherent risks and uncertainties and are subject to factors, many
of which are beyond the Company's control, such as market acceptance of new
products and services, changes in governmental regulations, interest rates,
fluctuations in currency exchange rates and such other factors as may be
discussed from time to time that may cause actual results or performance to
differ materially from those currently anticipated in such statements. These
expectations, estimates and projections are generally identifiable by
statements containing words such as "expects", "believes", "estimates" or
similar expressions. Although Cyplasin Biomedical Ltd believes that its
expectations and the information in this press release were based upon
reasonable assumptions at the time they were made, it can give no assurance
any expectations will be achieved or that the actual results will be as set
out in this press release. The Company makes no representation or warranty,
expressed or implied, as to the accuracy, reliability or completeness of the
information in the press release, and neither Cyplasin Biomedical nor any of
their directors, officers or employees will have any liability to you or any
other persons resulting from your use of the information in the press release.
The OTCBB Exchange has not reviewed and does not accept responsibility for the
adequacy or accuracy of this news release.

For further information:

For further information: Garth Likes, President & CEO, Cyplasin
Biomedical Ltd., Direct phone (780) 469-CYPL(2975), FAX Number (780) 699-7933,
Email Address, Website URL

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890